trial · primary record
Olpasiran
Hepatic Impairment
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 25 |
| Primary completion | 2023-05-31 |
| Primary endpoint | Maximum Observed Serum Concentration (Cmax) of Olpasiran |
| Registry ID | NCT05481411 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:51.925Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05481411
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.